INTRODUCTION.
The importance of cell cycle regulatory proteins, their direct interaction with oncogenes and the tumour suppressor pRb and their frequent deregulation in human tumours has encouraged an active search for low-molecular weight regulators of these proteins. Among them the chemical inhibitors of cyclin-dependent kinases were the first discovered. These inhibitors are anti-mitotic and display very interesting anti-tumour activities.
METHODS.
Chemical synthesis was based on alkylation of 2,6-dichloropurine. Newly developed compounds were then tested in different CDK assays (1) . Antiproliferative, cytotoxic and pro-differentiating capacity of olomoucine and its structural derivatives on the range of human and animal cell lines. We have been using the following cell lines: HELA (human cervical carcinoma), MCF7 (human breast adenocarcinoma), NIH 3T3 (mouse fibroblasts), HOS (human osteogenic sarcoma), HL 60 (human promyelocytic leukemia), G 361 (human malignant melanoma), K562 (human erythroleukaemia), CEM (human lymphoblastoid leukaemia). Tested drugs were added to the cell cultures in six different concentrations and kept at 37 o C and 5% CO 2 for three days. After that, viability of cells in cultures was examined by calcein AM assay. The concentration killing 50% of tumour cells will be calculated.
RESULTS.
Our research focused on the primary mechanism of action of plant hormones cytokinins (N 6 -substituted adenine derivatives) in cell division cycle has showed that natural plant cytokinins are rather non-specific inhibitors of various protein kinases (2) . Surprisingly, among aromatic cytokinin derivatives, we have discovered a compound, 2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine, named "olomoucine" (OC, Fig. 1 ), which specifically inhibits some cyclin-dependent kinases (CDKs) at micromolar concentration (2) . One of the inhibited kinases, the p34 cdc2 /cyclin B kinase, assumed to be a key mitotic factor, which is highly conserved and strongly implicated in cell cycle transitions in all eukaryotic cells (3) . The total lack of the inhibitory effect of olomoucine on major kinases, such as cAMPand cGMP-dependent kinases, protein kinase C, and others, suggests that OC might be a useful tool for cell cycle regulation studies. The design and inhibitory activity of OC was further improved by modifications at positions 2, 6,and 9, i.e., the positions that control binding to CDK1. This has recently led to discovery of novel specific CDK inhibitor named roscovitine, purvalanol A and B, etc. (1,4; Fig. 1 ), which displays an enhanced inhibitory activity toward CDK1, a higher selectivity toward some CDKs, an increased antimitotic activity at the G1/S and G2/M points of the cell cycle, and stronger and more selective antitumor effects. Finally, we have tested different CDK inhibitors on several tumour cell lines (CEM, HL 60, etc.). The average concentration that causes 50% growth inhibition is 2-100 µM. 
DISCUSSION.
Being stimulated by discovery of olomoucine many other groups have started to synthesise purine-derived CDK inhibitors (5, 6) . There are also other types of CDK inhibitors structurally unrelated with the trisubstituted purines.
